About us
MANAGEMENT TEAM
BOARD OF DIRECTORS
LEGAL
CONTACT US
PRODUCTS
REPORTING AN ADVERSE EVENT
PIPELINE
TECHNOLOGY PARTNERSHIPS
COMMERCIAL PARTNERSHIPS
Patients
PATIENT ADVOCACY
COMPASSIONATE USE
NEWS
CAREERS
Loading...
NEWS
Our latest news and press releases.
NEWS
admin
2020-09-15T09:44:20+00:00
US FDA GRANTS ONCE DAILY DOSING OPTION FOR NITYR (NITISINONE) TABLETS FOR HT-1 PATIENTS
Holly Archer
2020-09-14T14:08:02+00:00
US FDA Grants Once Daily Dosing Option For NITYR (nitisinone) Tablets for HT-1 Patients
Holly Archer
2020-09-09T11:01:19+00:00
Dr David Buckeridge Joins Cycle Pharmaceuticals’ Board of Directors
Holly Archer
2020-09-18T12:12:41+00:00
Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020
web_admin
2020-09-07T06:48:28+00:00
Cycle Pharmaceuticals Secures $25 Million Debt Financing
Holly Archer
2020-08-18T09:12:28+00:00
Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)
Holly Archer
2020-05-13T18:23:44+00:00
Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia
Holly Archer
2020-05-05T00:31:37+00:00
Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology
Holly Archer
2020-04-19T01:30:03+00:00
Cycle Pharmaceuticals Launches New Informative Online Meeting Series for Patients With Tyrosinemia Type 1 in the US
Web_Admin
2020-03-13T16:57:05+00:00
Cycle Pharmaceuticals’ Supply Chain update
Holly Archer
2019-12-18T16:17:54+00:00
Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics
FOLLOW US
ABOUT US
TECHNOLOGY PARTNERSHIPS
